LA JOLLA, Calif., Oct. 7 /PRNewswire/ -- The Board of Directors of Neurome, Inc., a privately held biotechnology company, today announced the appointment of Michael Khoury and Joseph Wender to its Board of Directors.
Joseph Wender is an Advisory Director and Senior Director of the Financial Institutions Group at the global investment banking firm, Goldman, Sachs & Co., and Michael Khoury is a financial advisor and independent consultant. These additions bring Neurome's total Board membership to six.
Commenting on the new appointments to the Board, Floyd E. Bloom, M.D., Chairman of the Board and Founding Chief Executive Officer of Neurome, remarked, "Joe Wender and Michael Khoury, both seasoned biotech investors and experienced financial professionals, complement the strengths of our current Board. We are gratified by their expressions of confidence in Neurome and look forward to their important contributions to our evolution as a leader in discovery and development of product solutions for human neurodegenerative disease."
Michael Khoury joined Deloitte & Touche, one of the nation's leading professional services firms, in 1989 and served as Senior Manager until 1993. From 1993 to 1998 Mr. Khoury served as first President, then CEO of First National Mortgage Exchange. He was Senior Vice President at IMC Mortgage, a consumer finance company, from 1998 to 1999. In 1999 he was appointed CEO of InterScore, a consulting firm that he sold in 2000 to Ballantyne, Inc., a consulting firm focused on Enterprise Resource Planning systems, where he remained as a Senior Vice President until 2003. He holds a B.S. in Mathematics from the American University of Beirut, an MFA from New York University, and an MBA from UCLA. He is a CPA and a Fulbright Scholar.
Joseph H. Wender joined Goldman Sachs in 1971 and became a General Partner of that firm in 1982 and a Limited Partner in 1992. He has been involved in most large mergers in the banking industry over the 80's and 90's, including the BankAmerica/Nations merger, the Wells Fargo/Norwest merger, and the Chase/Chemical merger. Mr. Wender sits on the board of Isis Pharmaceuticals, First Coastal Bancshares, and Affinity Financial. He is the President of the American Center for Wine, Food & the Arts, and is a Life Director of The Chicago Joffrey Ballet as well as a Member of the Board of Directors of the Actors' Fund. Mr. Wender received his Bachelors degree from Northwestern University, his LLB from Yale Law School, and his MBA from Harvard Business School.
Neurome, Inc. is a discovery stage biotechnology company that seeks therapeutic solutions to human neurodegenerative diseases. The company focuses its efforts on Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) -- usually fatal neurodegenerative disorders that are currently untreatable and share characteristics which make them particularly amenable to Neurome's expertise and technologies.
Since its founding in 2000, Neurome has developed and optimized proprietary technologies to reveal and quantify gene expression patterns and the resultant morphological details of brain structures in normal and pathological brains with an unprecedented level of sensitivity, specificity and resolution. Neurome's unique technologies to measure and assess neurodegenerative processes at work -- at the molecular, cellular and macroscopic levels -- are ideally suited to identify the earliest evidence of pathology in models of human diseases of the Central Nervous System, as well as to evaluate the comparative effectiveness of pharmaceutical candidates for intervention. The company dedicates these technologies to discovery and development of drugs to provide effective treatments for diseases characterized by neurodegeneration. Detailed information on the Neurome technologies and the scientific and medical challenges of human neurodegenerative disorders are available at Neurome's website: http://www.neurome.com/.